Address
349 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
650 938 6300
Website
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
560
First IPO Date
November 23, 2020
| Name | Title | Pay | Year Born |
| Joseph Selsavage | Interim Chief Executive Officer, Chief Financial & Accounting Officer | 624,493 | 1964 |
| Anne Wojcicki | Co-Founder & President | 65,000 | N/A |
| Daniel Chu | Chief Product Officer | 0 | N/A |
| Tracy Keim | Chief Marketing Officer | 0 | N/A |
| Kent Hillyer | Vice President of Consumer Operations | 0 | 1968 |
| Matthew E. Kvarda | Chief Restructuring Officer | 0 | 1972 |
| Savita Pillai | Vice President of People | 0 | N/A |
| Adam Auton | Vice President of Human Genetics | 0 | N/A |
| Frank Russo | Chief Security Officer | 0 | N/A |
| Guy Chayoun | Vice President, Interim General Counsel & Corporate Secretary | 0 | N/A |
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.